Remote cardiac rehabilitation

Transcatheter aortic valve replacement for aortic stenosis.

Use of SGLT2 inhibitors such as dapagliflozin and empagliflozin across heart failure types.

Drugs such as mavacamten and aficamten for hypertrophic cardiomyopathy.

An siRNA drug that lowers LDL cholesterol by reducing PCSK9 production in the liver.

Key point: Inclisiran achieves similar LDL-C reductions with biannual dosing, potentially improving adherence, though cardiovascular outcome data are pending.

A newer class of anticoagulants that target factor XI or XIa.

Key point: Adding an FXIa inhibitor to standard antiplatelet therapy after acute noncardioembolic ischemic stroke or TIA reduces stroke recurrence without evidence of increased bleeding risk.

Colchicine as an anti-inflammatory therapy in coronary and cardiovascular disease.

Key point: Low-dose colchicine has demonstrated modest reductions in cardiovascular events, although results across trials have been inconsistent.